A woman kneels to help a young girl with her coat in an emergent, softly lit entryway near a door and wooden bench. Light filters in from outside, creating a warm and cozy atmosphere.

PREPAREDNESS TODAY, SAFER TOMORROW.

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

A man in a pink sweater stands next to a whiteboard with handwritten notes, looking upward with a thoughtful expression as if considering emergent ideas. The writing on the board is partially blurred and difficult to read.

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)].
Read More

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in several upcoming conferences.
Read More

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.
Read More
READ ALL NEWS